Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Rinaldi

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.
JAMA Oncology|April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical TrialDavid Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohortDavid Tougeron, Frederic Bibeau, Benoist Chibaudel, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.
JAMA Oncology|April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical TrialDavid Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohortDavid Tougeron, Frederic Bibeau, Benoist Chibaudel, et al.
Pageof 3